Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) — Cash Flow Quality Index
Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) has a Cash Flow Quality Index of 2.27x as of September 2025. Operating cash flow of CN¥76.07 Million exceeds net income of CN¥33.45 Million, indicating high earnings quality where cash backs reported profits. Also explore 688621 current and non-current assets for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Beijing Sun Novo Pharmaceutical Research Co Ltd Cash Flow Quality Index (2017–2024)
Historical Cash Flow Quality Index for Beijing Sun Novo Pharmaceutical Research Co Ltd across 8 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Beijing Sun Novo Pharmaceutical Research tangible equity quality to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Beijing Sun Novo Pharmaceutical Research Co Ltd (2017–2024)
Year-by-year earnings quality comparison for Beijing Sun Novo Pharmaceutical Research Co Ltd. For live market cap and the full company financial profile, see market value of Beijing Sun Novo Pharmaceutical Research.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 0.19x | CN¥32.02 Million | CN¥169.01 Million | ▼ -62.7% |
| 2023 | 0.51x | CN¥92.86 Million | CN¥182.90 Million | ▼ -22.8% |
| 2022 | 0.66x | CN¥103.96 Million | CN¥158.04 Million | ▼ -18.9% |
| 2021 | 0.81x | CN¥88.25 Million | CN¥108.79 Million | ▼ -4.5% |
| 2020 | 0.85x | CN¥62.99 Million | CN¥74.16 Million | ▼ -28.5% |
| 2019 | 1.19x | CN¥56.97 Million | CN¥47.93 Million | ▼ -45.7% |
| 2018 | 2.19x | CN¥44.11 Million | CN¥20.16 Million | ▼ -69.4% |
| 2017 | 7.14x | CN¥8.01 Million | CN¥1.12 Million | — |